Effect of silibinin on the growth and progression of primary lung tumors in mice

J Natl Cancer Inst. 2006 Jun 21;98(12):846-55. doi: 10.1093/jnci/djj231.

Abstract

Background: Silibinin, a flavanone from milk thistle, inhibits the growth of tumors in several rodent models. We examined the effects of dietary silibinin on the growth, progression, and angiogenesis of urethane-induced lung tumors in mice.

Methods: A/J mice (15 per group) were injected with urethane (1 mg/g body weight) or saline alone and fed normal diets for 2 weeks, after which they were fed diets containing different doses of silibinin (0%-1% [wt/wt] silibinin) for 18 or 27 weeks. Immunohistochemistry and Western blot analysis were used to examine angiogenesis and enzymatic markers of inflammation, proliferation, and apoptosis. All statistical tests were two-sided.

Results: Urethane-injected mice exposed to silibinin had statistically significantly lower lung tumor multiplicities than urethane-injected mice fed the control diet lacking silibinin (i.e., control mice). Mice that received urethane and 1% (wt/wt) dietary silibinin for 18 weeks had 93% fewer large (i.e., 1.5-2.5-mm-diameter) lung tumors than control mice (mean number of tumors/mouse: 27 in the urethane group versus 2 in the urethane + 1% silibinin group, difference = 25 tumors/mouse, 95% confidence interval [CI] = 13 to 37 tumors/mouse, P = .005). Lung tumors of silibinin-fed mice had 41%-74% fewer cells positive for the cell proliferation markers proliferating cell nuclear antigen and cyclin D1 than lung tumors of control mice. Tumor microvessel density was reduced by up to 89% with silibinin treatment (e.g., 56 microvessels/400x field in tumors from control mice versus 6 microvessels/400x field in tumors from urethane + 1% silibinin-treated mice [difference = 50 microvessels/400x field, 95% CI = 46 to 54 microvessels/400x field; P<.001]). Silibinin decreased lung tumor expression of vascular endothelial growth factor (VEGF) and of inducible nitric oxide synthase and cyclooxygenase-2, two enzymes that promote lung tumor growth and progression by inducing VEGF expression.

Conclusions: Silibinin inhibits lung tumor angiogenesis in an animal model and merits investigation as a chemopreventive agent for suppressing lung cancer progression.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Biomarkers, Tumor / metabolism*
  • Blotting, Western
  • Carcinogens
  • Cell Proliferation / drug effects
  • Cyclin D1 / drug effects
  • Cyclooxygenase 2 / drug effects
  • Disease Models, Animal
  • Fibroblast Growth Factor 2 / drug effects
  • Immunohistochemistry
  • Inflammation / drug therapy
  • Lung Neoplasms / blood supply
  • Lung Neoplasms / chemically induced
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / pathology
  • Mice
  • Microcirculation / drug effects
  • Neovascularization, Pathologic / drug therapy
  • Nitric Oxide Synthase Type II / drug effects
  • Platelet Endothelial Cell Adhesion Molecule-1 / drug effects
  • Proliferating Cell Nuclear Antigen / metabolism
  • Silybin
  • Silymarin / pharmacology
  • Urethane
  • Vascular Endothelial Growth Factor A / drug effects

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Carcinogens
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Proliferating Cell Nuclear Antigen
  • Silymarin
  • Vascular Endothelial Growth Factor A
  • Fibroblast Growth Factor 2
  • Cyclin D1
  • Urethane
  • Silybin
  • Nitric Oxide Synthase Type II
  • Cyclooxygenase 2